Table 1—

Patient characteristics at screening (week −4)

EXUSubcutaneous insulin
Sex (male/female)205/111 (65/35)193/118 (62/38)
Race
    White234 (74.1)222 (71.4)
    Black28 (8.9)28 (9.0)
    Asian6 (1.9)6 (1.9)
    Hispanic38 (12.0)42 (13.5)
    Other10 (3.2)13 (4.2)
Age (years)56.7 ± 9.255.5 ± 9.9
Weight (kg)87.1 ± 14.888.3 ± 15.4
Height (cm)171.0 ± 9.7170.9 ± 10.1
BMI (kg/m2)29.6 ± 4.030.1 ± 3.9
A1C (%)8.02 ± 1.268.15 ± 1.30
C-peptide (pmol/ml)0.43 ± 0.370.36 ± 0.25
Time since diagnosis of diabetes (years)13.7 (0.7–43.3)13.7 (0.5–40.2)
FEV1*
    Observed (liters)2.91 ± 0.682.93 ± 0.71
    Predicted (%)90.9 ± 11.891.2 ± 12.6
DLCO*
    Observed (ml · min−1 · mmHg−1)24.17 ± 5.5823.99 ± 5.72
    Predicted (%)92.3 ± 14.191.5 ± 12.7
  • Data are n (%), means ± SD, or mean (range).

  • * FEV1 and DLCO test values at study entry were defined as the means of the values obtained at weeks −2 and −1.